Skip to main content
SpringerLink
Log in

Erectile Dysfunction Associated with Pharmacological Agents

  • Chapter
Diagnosis and Treatment of Erectile Disturbances

Abstract

The purpose of this chapter is to review pharmacological effects on male erectile dysfunction. As will be documented in this chapter, a wide variety of pharmacological agents have been reported to have sexual side effects. Drugs may influence male sexual function at various levels including (1) sexual interest or desire (also termed libido), (2) the capacity to achieve and maintain an erection sufficient for coitus, (3) ejaculation, and (4) fertility. Although the issue of fertility is beyond the scope of this review, drugs that inhibit fertility often suppress hormonal secretions and may thus influence sexual behavior. This text is concerned primarly with erectile function. However, libido and ejaculation problems often coexist and interact with erectile problems. The effects of drugs on these sexual activities will also be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Benedek TG: Aphrodisiacs: Facts and fable. Med Aspects Hum Sexuality 5: 42–45, 1971

    Google Scholar 

  2. Brown-Sequard CE: Des effets produits chez l’homme par des injections sauscutanees d’un liquide retine des testicules frais de cubaze et de chien. Seane Soci Biol 1: 420–430, 1889

    Google Scholar 

  3. Davidson JM, Kwan M, Greenleaf WF: Hormonal replacement and sexuality in men. Clin Endocrinol Metab 11: 599, 1982

    CAS  PubMed  Google Scholar 

  4. Bremer J: Asexualization: A follow-up study of 244 cases. New York, Macmillan, 1959

    Google Scholar 

  5. Segraves RT, Schoenberg HW, Ivanoff J: Serum testosterone and prolactin levels in erectile dysfunction. ] Sex Marital Ther 9: 19–26, 1973

    Google Scholar 

  6. Bancroft J: Endocrinology of sexual function. Clin Obstet Gynecol 7: 253, 1980

    CAS  Google Scholar 

  7. Gessa GL, Tagliamonte A: Role of brain monoamines in male sexual behavior. Life Sci 14: 425–436, 1974

    CAS  PubMed  Google Scholar 

  8. Gessa GL, Tagliamonte A: Role of brain serotonin and dopamine in male sexual behavior, in Sandler M, Gessa GL (eds): Sexual Behavior: Pharmacology and Biochemistry. New York, Raven Press, 1975

    Google Scholar 

  9. Goodwin FK: Behavioral effects of L-dopa in man, in Shader R (ed): Psychiatric Complications of Medical Drugs. New York, Raven Press, 1972

    Google Scholar 

  10. O’Brien CP, DiGiacomo JN, Fahn S, et al: Mental effects of high-dosage levodopa. Arch Gen Psychiatry 24: 61–72, 1971

    PubMed  Google Scholar 

  11. Angrist B, Gershon S: Clinical effects of amphetamine and L-dopa on sexuality and aggression. Compr Psychiatry 17: 715–722, 1976

    CAS  PubMed  Google Scholar 

  12. Brogden RN, Speight TM, Avery GS: Levodopa-Review of its pharmacological properties and therapeutic uses with particular reference to parkinsonism. Drugs 2: 257–409, 1971

    Google Scholar 

  13. Hallstrom T, Persson T: L-dopa and non-emission of semen. Lancet 1: 1231–1232, 1970

    CAS  PubMed  Google Scholar 

  14. Thorner MO, Besser GM: Hyperprolactinaemia and gonadal function: Results of bromocriptine treatment, in Crosignani PG, Robyn C (eds): Prolactin and Human Reproduction. London, Academic Press, 1977

    Google Scholar 

  15. Carter JN, Tyson JE, Tolis G, et al: Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 229: 847–851, 1978

    Google Scholar 

  16. Pierini AA, Nusimovich B: Male diabetic sexual impotence: Effects of dopaminergic agents. Arch Androl 6: 347–350, 1981

    CAS  PubMed  Google Scholar 

  17. Ambrosi B, Bara R, Travaglini P, et al: Study of the effects of bromocriptine on sexual impotence. Clin Endocrinol 7: 417–421, 1977

    CAS  Google Scholar 

  18. Sicuteri F: Serotonin and sex in man. Pharmacol Res Communi 4: 403–411, 1974

    Google Scholar 

  19. Sicuteri F, Bene ED, Anselmi B: Aphrodisiac effects of testosterone in parachloro-phenylalnine-treated sexually deficient men, in Sandler M, Gessa GL (eds): Sexual Behavior: Pharmacology and Biochemistry. New York, Raven Press, 1985

    Google Scholar 

  20. Ambrosi B, Travaglini P, Gaggini M, et al: Effects of serotonin antagonists in sexually impotent men. Andrologia 6; 475–477, 1979

    Google Scholar 

  21. Masters WH, Johnson VE: Human Sexual Response. Boston, Little Brown, 1966

    Google Scholar 

  22. Kaplan HS: The New Sex Therapy. New York, Brunner/Mazel, 1974

    Google Scholar 

  23. Farkas GM, Rosen RC: Effects of alcohol on elicited male sexual response. J Stud Alcohol 37: 265, 1976

    CAS  PubMed  Google Scholar 

  24. Bridell DW, Wilson JT: Effect of alcohol and expectancy set on male sexual arousal. I Abnorm Psychol 85: 225–234, 1976

    Google Scholar 

  25. Abel EL: A review of alcohol’s effects on sex and reporduction. Drug Alcohol Dependence 5: 321–332, 1980

    CAS  PubMed  Google Scholar 

  26. Lemere F, Smith JW: Alcohol-induced sexual impotence. Am ] Psychiatry 130: 212–213, 1973

    CAS  PubMed  Google Scholar 

  27. Whalley LJ: Sexual adjustment of male alcoholics. Acta Psychiatr Scand 58: 281–288, 1978

    CAS  PubMed  Google Scholar 

  28. Akhtar MJ: Sexual disorders in male alcoholics, in Madden JS, Walker R, Kenyon WH (eds): Alcoholism and Drug Dependence. A Multidisciplinar Approach. New York, Plenum Press, 1977

    Google Scholar 

  29. Malatesta VJ, Pollack RH, Wilbanks WA, et al: Alcohol effects on the orgasmic-ejac-ulatory response in human males. J Sex Res 2: 101–107, 1979

    Google Scholar 

  30. Hart BL: Effects of alcohol on sexual reflexes and mating behavior in the male rat. Psychopharmacologia 14: 377–382, 1969

    CAS  PubMed  Google Scholar 

  31. Sheldon CH, Bors E: Subarachnoid alcohol block in paraplegia: Its beneficial effect on mass reflexes and bladder dysfunction. ] Neuro Surg 5: 385–391, 1948

    Google Scholar 

  32. Novak DJ, Victor M: The vagus and sympathetic nerves in alcoholic polyneuropathy. Arch Neurol 30: 273–284, 1974

    CAS  PubMed  Google Scholar 

  33. Hollister LE: Drugs and sexual behavior in man. Life Sci 17: 661–666, 1975

    CAS  PubMed  Google Scholar 

  34. Kolodny RC, Masters WH, Kolodner RM, et al: Depression of plasma testosterone levels after chronic intensive marijuana use. N Engl J Med 290: 872, 1974

    CAS  PubMed  Google Scholar 

  35. Mendelson JH, Kuehnle L, Ellinbgo J: Plasma testosterone levels before during and after chronic marijuana smoking. N Engl J Med 291: 1051, 1974

    CAS  PubMed  Google Scholar 

  36. Oaks WW, Moyer JH: Sex and hypertension. Med Aspects Hum Sexuality 61: 128–137, 1972

    Google Scholar 

  37. Berman EM, Lief HI: Sex and the aging process, in Paks WW, Melchiode GA, Ficher I (eds): Sex and the Life Cycle. New York, Grune & Stratton, 1976

    Google Scholar 

  38. McMahon FG: Management of Essential Hypertension. Mount Kisco, New York, Futura, 1978

    Google Scholar 

  39. Segraves RT: Pharmacological agents causing sexual dysfunction. ]Sex Marital Ther 3: 157–176, 1977

    Google Scholar 

  40. Munjack DJ: Sex and drugs. Clin Toxicol 15: 75–89, 1979

    CAS  Google Scholar 

  41. Mills LC: Drug-induced impotence. Am Fam Physician 12: 104–106, 1975

    CAS  PubMed  Google Scholar 

  42. Horowitz JD, Goble AJ: Drugs and impaired male sexual function. Drugs 18: 206–217, 1979

    CAS  PubMed  Google Scholar 

  43. Story NL: Sexual dysfunction resulting from drug sale effects. J Sex Res 10: 132–149, 1974

    CAS  PubMed  Google Scholar 

  44. Hogan MJ, Wallin JD, Baer RM: Antihypertensive therapy and male sexual dysfunction. Psychosomatics 12: 234–237, 1980

    Google Scholar 

  45. Keidan H: Impotence during antihypertensive treatment. Can Med Assoc J 114: 874, 1976

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Boyden TW, Nugent CA, Ogihara T, et al: Reserpine hydrochlorothiazide and pituitary-gonadal hormones in hypertensive patients. Eur J Clin Pharmacol 17: 329–332, 1980

    CAS  PubMed  Google Scholar 

  47. Yendt ER, Gray GF, Garcia DA: The use of thiazides in the prevention of renal calculi. Can Med Assoc J 102: 614–620, 1970

    CAS  PubMed Central  PubMed  Google Scholar 

  48. Stressman J, Ben-Ishay D: Chlorthalidone-induced impotence. Br Med J 281: 714, 1980

    Google Scholar 

  49. Pillay VKG: Some side-effects of alpha-methyldopa. S Afr Med J 50: 625–626, 1976

    CAS  PubMed  Google Scholar 

  50. Medical Research Council working party on mild to moderate hypertension. Lancet 2: 539–542, 1981

    Google Scholar 

  51. Bulpitt CJ, Dollery CT: Side-effects of hypotensive agents evaluated by a self-admin-istered questionnaire. Br Med J 3: 485–490, 1973

    CAS  PubMed Central  PubMed  Google Scholar 

  52. Slag MF, Morley JE, Elson MK, et al: Impotence in medical clinical outpatients. JAMA 249: 1736–1740, 1983

    CAS  PubMed  Google Scholar 

  53. Papadopoulos C: Cardiovascular drugs and sexuality. Arch Intern Med 140: 1341–1345, 1980

    CAS  PubMed  Google Scholar 

  54. Loriaux DL, Menard R, Taylor A, et al: Spironolactone and endocrine dysfunction. Ann Intern Med 85: 630–636, 1976

    CAS  Google Scholar 

  55. Spark RF, Melby JC: Aldosteronism in hypertension. Ann Intern Med 69: 685–691, 1968

    CAS  PubMed  Google Scholar 

  56. Zarren HS, Black PM: Unilateral gynecomastia and impotence during low-dose spo-ronolactone administration in men. Mili Med 140: 417–419, 1975

    CAS  Google Scholar 

  57. Brown J, Davies DL, Ferriss JB, et al: Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J 1: 729–734, 1972

    Google Scholar 

  58. Greenbladt DJ, Koch-Weser J: Gynecomastia and impotence complications of spiron-lactone therapy. JAMA 233: 82, 1973

    Google Scholar 

  59. Fröhlich ED: Adrenergic inhibiting drugs, Hunt JC, Cooper T, Fröhlich ED (eds): in Hypertension Update: Mechanisms, Epidemiology, Evaluation, Management. Bloomfield, New Jersey, Health Learning Systems, 1980

    Google Scholar 

  60. Johnson P, Kitchin AH, Lowther CP, et al: Treatment of hypertension with methyldopa. Br Med J 1: 133–137, 1966

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Newman RJ, Salerno HR: Sexual dysfunction due to methyldopa. Br Med J 4: 106, 1974

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Dollery CT, Harington M: Methyldopa in hypertension. Lancet 1: 759–763, 1962

    CAS  PubMed  Google Scholar 

  63. Horwitz D, Pettinger WA, Oruis H, et al: Effects of methyldopa in fifty hypertensive patients. Clin Pharmacol Thera 8: 224–234, 1967

    CAS  Google Scholar 

  64. Mroczer WJ, Leibel BA, Finnerty FA: Comparison of Clonidine and methyldopa in hypertensive patients receiving a diuretic. Am J Cardiol 29: 712–717, 1972

    Google Scholar 

  65. Vejlsgaard V, Christensen M, Clasen E: Double-blind trial of four hypotensive drugs (methyldopa and three sympatholytic agents). Br Med J 2: 598–600, 1967

    CAS  PubMed Central  PubMed  Google Scholar 

  66. Prichard BNC, Johnston AW, Hill Id,. Bethanidine guanethidine, and methyldopa in treatment of hypertension: A within-patient comparison. Br Med J 1: 135–144, 1968

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Bauer GE, Hull RD, Stokes GS, et al: The reversibility of side-effects of guanethidine therapy. Med J Aust 1: 930–933, 1973

    CAS  PubMed  Google Scholar 

  68. Laver MC: Sexual behavior patterns in male hypertensives. Aust NZ J Med 4: 29–31, 1974

    CAS  Google Scholar 

  69. Lauwers P, Verstraete M, Joossen JV: Methyldopa in the treatment of hypertension. Br Med J 1: 295–300, 1963

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Bulpitt CJ, Dollery CT: Side effects of hypotensive agents evaluated by a self-administered questionnaire. Br Med J 1: 485–490, 1973

    Google Scholar 

  71. VA Cooperative Study Group on Antihypertensive Agents: Propranolol in the treatment of essential hypertension. JAMA 237: 2303–2310, 1977

    Google Scholar 

  72. Tuchman H, Crumptom CW: A comparison of Rauvolfia serpentia compounds cru-deroot, alseroxylon dervivative and single alkoloid in the treatment of hypertension. Am Heart J 49: 742–750, 1955

    CAS  PubMed  Google Scholar 

  73. Girgis SM, Etriby A, El-Hefnawy H, et al: Aspermia: A survey of 49 cases. Fertil Steril 19: 580–588, 1968

    CAS  PubMed  Google Scholar 

  74. Sah HJ, Sah PPT, Peoples SA: The new antihypertensive agent, guanethidine-a review. Arzneimittelforsch 16: 199–202, 1966

    CAS  PubMed  Google Scholar 

  75. Evans B, Iwayama T, Burnstock G: Long-lasting hypersensitivity of the rat vas defers to norepinephrine after chronic guanethidine administration. ]Pharmacol Exp Ther 185: 60–69, 1973

    CAS  Google Scholar 

  76. Evans B, Gannon BJ, Heatin JW, et al: Long-lasting damage to the internal male genital organs and their adrenergic inervation in rats following chronic treatment with the antihypertensive drug guanethidine. Fertil Steril 23: 657–667, 1972

    CAS  PubMed  Google Scholar 

  77. Reudy J, Davies RO: A comparative clinical trial of guanoxan and guanethidine in essential hypertension. Clin Pharmacol Ther 8: 38–47, 1967

    Google Scholar 

  78. Schinger A, Gifford RW: Guanethidine, a new antihypertensive agent: Experience in the treatment of patients with severe hypertension. Mayo Clin Proc 37: 100–108, 1962

    Google Scholar 

  79. Seedat YK, Pillay VKG: Further experiences with guanethidine-a clinical assessment of 103 patients. S Afr Med J 40: 140–143, 1966

    CAS  PubMed  Google Scholar 

  80. Eagen JT, Orgain ES: A study of 38 patients and their response to guanethidine. JAMA 1975: 550–553, 1961

    Google Scholar 

  81. Brown WJ, FIK: The use of guanethidine and hydrochlorothiazide in the long-term treatment of essential hypertension. Curr Ther Res 17: 544–554, 1975

    PubMed  Google Scholar 

  82. Lowther CP, Turner RW: Guanethidine in the treatment of hypertension. Br Med ] 2: 776–781, 1963

    CAS  Google Scholar 

  83. Bauer GE, Croll FJT, Goldrick RB, et al: Guanethidine in treatment of hypertension. Br Med J 2: 410–415, 1961

    CAS  PubMed Central  PubMed  Google Scholar 

  84. Oats JA, Seligmann AW, Clark MA, et al: The relative efficacy of guanethidine, meth-ydopa, and pargyline as antihypertensive agents. N Engl J Med 273: 729–731, 1965

    Google Scholar 

  85. Page IH, Hurley RE, Dustan HP: The prolonged treatment of hypertension with guanethidine. JAMA 175: 543–549, 1961

    CAS  PubMed  Google Scholar 

  86. Raftos J, Bauer GE, Lewis RG, et al: Clonidine in the treatment of severe hypertension. Med] Aust 30: 786–793, 1973

    Google Scholar 

  87. Saunders E, Kong B: Sexual activity in male hypertensive patients while taking Clonidine. Urban Health 9: 22–26, 1980

    Google Scholar 

  88. Amery A, Verstraete M, Bossaert H, et al: Hypotensive action and side effects of clonidine-chlorthalidone and methyldopa-chlorthalidone in treatment of hypertension. Br Med J 4: 392–395, 1970

    CAS  PubMed Central  PubMed  Google Scholar 

  89. MacDougall AI, Addis GJ, MacKay N, et al: Treatment of hypertension with Clonidine. Br Med J 3: 440–443, 1970

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Ebringer A, Doyle AE, Dawborn JK, et al: The use of Clonidine (catapres) in the treatment of hypertension. Med J Aust 1: 524–526, 1970

    Google Scholar 

  91. Khan A, Camel G, Perry HM: Clonidine (catapres): A new antihypertensive agent. Curr Ther Res 12: 10–18, 1970

    CAS  PubMed  Google Scholar 

  92. Onesti G, Bock KD, Heimsoth V, et al: Clonidine: A new antihypertensive agent. Am ] Cardiol 28: 74–83, 1971

    CAS  Google Scholar 

  93. Miller RA: Propranolol and impotence. Ann Intern Med 85, 683: 683, 1976

    Google Scholar 

  94. Knarr JW: Impotence from propranolol. Ann Intern Med 85: 295, 1976

    Google Scholar 

  95. Gavras I, Gavras H, Sullivan PC, et al: A comparative study of the effects of oxpernolol versus propranolol in essential hypertension. J Clin Pharmacol 19: 8–14, 1979

    CAS  PubMed  Google Scholar 

  96. Husserl FE, Messerli FH: Adverse effects of antihypertensive drugs. Drugs 22: 188–210, 1981

    CAS  PubMed  Google Scholar 

  97. Bathen J: Propranolol erectile dysfunction relieved. Ann Intern Med 88: 716–717, 1978

    CAS  PubMed  Google Scholar 

  98. Forsberg L, Gustauvil B, Hojerbach T, et al: Impotence, smoking, and B-blocking drugs. Fertil Steril 31: 589–591, 1979

    CAS  PubMed  Google Scholar 

  99. Burnett W, Chaline R: Sexual dysfunction as a complaint of propanolol therapy in men. Cardiovasc Med 4: 811–815, 1979

    Google Scholar 

  100. Serlin MS, Orme M, Baber N, et al: Propranolol in the control of blood pressure. Clin Pharmacol Ther 27: 586–592, 1980

    CAS  PubMed  Google Scholar 

  101. Warren SG, Brewer DL, Orgain ES: Long-term propranolol therapy for angina pectoris. Am J Cardiol 37: 420–426, 1976

    CAS  PubMed  Google Scholar 

  102. Warren SC, Warren SG: Propranolol and sexual impotence. Ann Intern Med 86: 112, 1977

    CAS  PubMed  Google Scholar 

  103. Hollifield JW, Sherman K, Zwagg RU, et al: Proposed mechanisms of propranolol’s antihypertensive effect in essential hypertension. N Engl ] Med 295: 68–73, 1976

    CAS  Google Scholar 

  104. Greminger P, Vetter HH, Boerlin HJ, et al: A comparative study between 100 mg atenolol and 20 mg pindolol slow-release in essential hypertension. Drugs 25 (supp 12): 36–41, 1983

    Google Scholar 

  105. Ambrosioni E, Costa FV, Montebugnoli L, et al: Comparison of antihypertensive efficacy of atenolol, Oxprenolol and pindolol at rest and during exercise. Drugs 25 (suppl 2): 30–36, 1983

    Google Scholar 

  106. Heel RC, Brodgen RN, Speight TM, et al: Atenolol: A review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension. Drugs 17: 425–460, 1979

    CAS  PubMed  Google Scholar 

  107. Osborne DR: Propranolol and Peyronie’s disease. Lancet 1: 1111, 1977

    CAS  PubMed  Google Scholar 

  108. Wallis AA, Bell R. Sutherland PW: Propranolol and Peyronie’s disease. Lancet 1: 980, 1977

    Google Scholar 

  109. Law MR, Copeland RFP, Armistad JG, et al: Lebetalol and priapism. Br Med J 1: 115, 1980

    Google Scholar 

  110. Keidan H: Impotence during antihypertensive treatment. J Can Med Assoc 114: 874, 1976

    CAS  Google Scholar 

  111. Ahmad S: Hydralazine and male impotence. Chest 78: 358, 1980

    CAS  PubMed  Google Scholar 

  112. Jandhyala BS, Clarke DE, Buckely JP: The effects of prolonged administration of certain antihypertensive agents. J Pharmacol Sei 63: 1497–1513, 1974

    CAS  Google Scholar 

  113. Vlachakis ND, Mendlowitz M: Alpha and beta-adrenergic receptor blocking agents combined with a diuretic in the treatment of essential hypertension. J Clin Pharmacol 111: 352–360, 1976

    Google Scholar 

  114. Lowew S, Puttuck SL: Anti-ejaculatory effect of sympatholytic gangliolytic and spasmolytic drugs. J Pharmacol Exp Ther 107: 379–384, 1953

    Google Scholar 

  115. Green M, Berman S: Failure of ejaculation produced by dibenzyline. Conn State Med ] 18: 30–34, 1954

    CAS  Google Scholar 

  116. Caine M, Perlberg S, Shapiro A: Phenoxybenzamine for benign prostatic obstruction. Urology 17: 542–546, 1981

    CAS  PubMed  Google Scholar 

  117. Kedia KR, Persky L: Effect of phenoxybenzamine (Dibenzyline) on sexual function in man. Urology 18: 620–622, 1981

    CAS  PubMed  Google Scholar 

  118. Kedia K, Markland C: Effect of sympathectomy and drugs on ejaculation, in Sciarra J], Markland C, Speidel JJ (eds): Control of Male Fertility. Hagerstown, Maryland, Harper & Row, 1975

    Google Scholar 

  119. Peart WS, MacMahan MT: Clinical trial of 2-guanidinomethylc (1,4) benzodioxan (compound 1003) Br Med ] 1: 398–402, 1964

    CAS  Google Scholar 

  120. Lawrie TDV, Lorimer AR, McAlpine DSG, Clinical trial and pharmacological study of compound 1029 (vatensor). Br Med ] 1: 402–406, 1964

    CAS  Google Scholar 

  121. Brogen RN, Heel RC, Speight TM,. Prazosin: A review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 163–197

    Google Scholar 

  122. Stokes GS, Oates HF: Prazosin: New alpha-adrenergic blocking agent in treatment of hypertension. Cardiovasc Med 3: 41–57, 1978

    CAS  Google Scholar 

  123. Amery A, Verhiest W, Croonenberghs J, et al: Double-blind crossover study with a new vasodilator-prazosin-in the treatment of mild hypertension. Exerpta Med Int Congress Series 331: 100–110, 1974

    Google Scholar 

  124. Kochar M, Zeller J, Itskovitz H: Prazosin in hypertension with and without methyldopa. Clin Pharmacol Ther 25: 143–148, 1979

    CAS  PubMed  Google Scholar 

  125. Pitts NE: A clinical evaluation of prazosin, a new antihypertensive agent. Postgrad Med 58: 117–127, 1975

    Google Scholar 

  126. Moser M, Prandoni AG, Orbison JA, et al: Clinical experience with sympathetic blocking agents in peripheral vascular disease. Ann Intern Med 38: 1245–1246, 1953

    CAS  PubMed  Google Scholar 

  127. Pentland B, Anderson DA, Critchley JAJ: Failure of ejaculation with indoramin. Br Med ] 282: 1433–1434, 1981

    CAS  Google Scholar 

  128. Lewis PJ, George CJ, Dollery CT: Clinical evaluation of indoramin, a new antihypertensive agent. Eur J Clin Pharmacol 6: 211–216, 1973

    CAS  PubMed  Google Scholar 

  129. Faerchtein I, Roque AF, Kastansky I, et al: A placebo controlled trial of the alpha-blocker, indoramin, in the treatment of arterial hypertension. CurrMed Res Opinion 3: 675–684, 1976

    Google Scholar 

  130. Hollister LE: Drugs and sexual behavior in man. Life Sei 17: 661–667, 1977

    Google Scholar 

  131. Mitchell JE, Popkin MK: Antipsychotic drug therapy and sexual dysfunction in men. Am ] Psychiatry 139, 633–637, 1982

    CAS  Google Scholar 

  132. Zaratzian VL: Psychotropic drugs-neurotoxicity. Clin Toxicol 17: 231–270, 1980

    CAS  PubMed  Google Scholar 

  133. Barnes TRE, Bamber RWK, Watson JP: Psychotropic drugs and sexual behavior. Br ] Hosp Med 12: 594–599, 1979

    Google Scholar 

  134. Nestoros JN, Lehmann HE: Neuroleptics and male sexual dysfunction. Int Drug Ther Newsletter 14: 21–23, 1979

    Google Scholar 

  135. Laughren T, Brown W, Petrucci J: Effects of thioridazine on serum testosterone. Am J Psychiatry 135: 982–984, 1978

    CAS  PubMed  Google Scholar 

  136. Amdur M: Confirming a side effect. Am ] Psychiatry 133: 864, 1976

    Google Scholar 

  137. Sandison RA, Whitelaw E, Currie JDC: Clinical trails with Mellaril (TP21) in the treatment of schizophrenia. ] Ment Sei 106: 732–741, 1960

    CAS  Google Scholar 

  138. Freyhan FA: Loss of ejaculation during Mellanil treatment. Am ]Psychiatry 118: 171–172, 1961

    CAS  Google Scholar 

  139. Haider I: Thioridazine and sexual dysfunctions. Int J Neuropsychiatry 2: 255–257, 1962

    Google Scholar 

  140. Shader RI: Sexual dysfunction associated with thioridazine hydrochloride. JAMA 188: 1007–1009, 1964

    CAS  PubMed  Google Scholar 

  141. Clein L: Thioridazine and ejaculation. Br Med J 2: 548–549, 1962

    PubMed Central  Google Scholar 

  142. Datshkovsky J: Mellaril: Ejaculation disorders. Am J Psychiatry 118: 564, 1961

    Google Scholar 

  143. Singh H: A case of inhibition of ejaculation as a side effect of Mellaril. Am ] Psychiatry 117: 1041, 1961

    Google Scholar 

  144. Singh H: Therapeutic use of thioridazine in premature ejaculation. Am J Psychiatry 119: 891, 1963

    CAS  PubMed  Google Scholar 

  145. Witton K: Sexual dysfunction secondary to Mellaril. Dis Nerv Syst 23: 175, 1962

    CAS  PubMed  Google Scholar 

  146. Shader RI: Ejaculation disorders, in Shader RI, DiMascio A (eds): Psychotropic Drug Side Effects. Baltimore, Williams & Wilkins Co., 1970

    Google Scholar 

  147. Mellgren A: Treatment of ejaculatio praecox with thioridazine Psychother Psychosom 15: 454–460, 1967

    Google Scholar 

  148. Money J, Yankowitz, R., The sympathetic-inhibiting effects of the drug Ismelin on human male eroticism, with a note on Mellaril. ] Sex Res 3: 69–82, 1967

    Google Scholar 

  149. Taubel DE: Mellaril: Ejaculation disorders. Am J Psychiatry 119: 87, 1962

    Google Scholar 

  150. Greenberg HR, Carrillo C: Thioridazine-induced inhibition of mastubatory ejaculation in an adolescent. Am ] Psychiatry 124: 991–993, 1968

    CAS  Google Scholar 

  151. Heaton-Ward WA: The present position of the use of tranquilizers in psychiatric patients. Curr Med Drugs 6: 14–20, 1965

    Google Scholar 

  152. Heller J: Another case of inhibition of ejaculation as a side effect of Mellaril. Am ] Psychiatry 118: 173, 1961

    CAS  Google Scholar 

  153. Green M: Inhibition of ejaculation as a side effect of Mellaril. Am ] Psychiatry 118: 172–173, 1961

    CAS  Google Scholar 

  154. Shader R, Grinspoon L: Schizophrenia, oligospermia, and the phenothiazines. Dis Nero Syst 28: 240–244, 1967

    CAS  Google Scholar 

  155. Kotin J, Wilbert DE, Verbürg D, et al: Thioridazine and sexual dysfunction. Am J Psychiatry 133: 82–85, 1976

    CAS  PubMed  Google Scholar 

  156. Quershi MS: Thioridazine and ejaculation. Medicus (Kanachi) 15: 39, 1962

    Google Scholar 

  157. Dorman BW, Schmidt JD: Association of priapism in phenothiazine therapy. J Urol 116: 51–53, 1976

    CAS  PubMed  Google Scholar 

  158. Dahl DS, Middleton RG: Comparison between cavernoscephenous and cavernospon-giosum shunting in the treatment of idiopathic priapism: A report of 5 operations. J Urol 112: 614, 1974

    CAS  PubMed  Google Scholar 

  159. Schmidt JD: Intracorporal shunt procedures for priapism. Arch Surg 103: 409, 1971

    CAS  PubMed  Google Scholar 

  160. Shengy RS: Nocturnal enuresis caused by psychotropic drugs. Am J Psychiatry 137: 739–740, 1980

    Google Scholar 

  161. Greenberg HR: Inhibition of ejaculation by chlorpromazine. J Nerv Ment Dis 152: 364–366, 1971

    CAS  PubMed  Google Scholar 

  162. Bolelovcky Z: Chlorpromazine inhibition of ejaculation. Act Nero Super (Praha) 7: 245, 1965

    Google Scholar 

  163. Tennett G, Bancroft J, Cass J: The control of deviant sexual behavior by drugs: A double-blind controlled study of benperidol, chlorpromazine and placebo. Arch Sex Behav 3: 261–271, 1974

    Google Scholar 

  164. Dawson-Butterworth K: Idiopathic priapism associated with schizophrenia. Br J Clin Pract 23: 125–126, 1969

    CAS  PubMed  Google Scholar 

  165. Meiraz D, Fishelovitch J: Priaspism and largactil medication. Isr J Med Sei 51: 1254–1255, 1969

    Google Scholar 

  166. Larocque MA, Cosgrove MD: Priapism: A review of 46 cases. J Urol 112: 770–773, 1974

    CAS  PubMed  Google Scholar 

  167. Bastecky J, Gregova L: Priapism as a possible complication of the chlorpromazine treatment. Activ Nerv Supp 16: 175, 1974

    CAS  Google Scholar 

  168. Dawson-Butterworth K: Priapism and phenothiazines. Br Med J 4: 118, 1970

    CAS  PubMed Central  PubMed  Google Scholar 

  169. Merkin TE: Priapism as a sequela of chlorpromazine therapy. JACEP 6: 367–368, 1977

    CAS  PubMed  Google Scholar 

  170. Ditman KS: Inhibition of ejaculation by chloroprothixine. Am J Psychiatry 120:1004–1O05, 1964

    Google Scholar 

  171. Shader RI: Sexual dysfunction associated with mesoridazine besylate (Serentil). Psy-chopharmacologia 27: 293–294, 1972

    CAS  Google Scholar 

  172. Gottlieb JI, Lustberg T: Phenothiazine-induced priapism: A case report. Am J Psychiatry 134: 1445–1446, 1977

    CAS  PubMed  Google Scholar 

  173. Bartholomew AA: A long-acting phenothiazine as a possible agent to control deviant sexual behavior. Am J Psychiatry 124: 77–83, 1968

    Google Scholar 

  174. Dillon JB, Bates TJN: Fluphenazine enanthate in the maintenance treatment of schizophrenia. Br Med J 2: 1328, 1966

    PubMed Central  Google Scholar 

  175. Charalampous KD, Freemesser GF, Malev J, et al: Loxapine succinate: A controlled double-blind study in schizophrenia. Curr Ther Res 16: 829–837, 1974

    CAS  PubMed  Google Scholar 

  176. Goldstein B, Weiner D, Banas F: Clinical evaluation of thiothixine in chronic ambulatory schizophrenic patients, in Lehmann HE, Bann TA (eds): The Thioxanthenes: Modern Problems in Pharmacopsychiatry, Volume 2. New York, Kargen, 1969

    Google Scholar 

  177. Blair JH, Simpson GM: Effects of antipsychotic drugs on reproductive functions. Dis Nerv Syst 27: 645–647, 1966

    CAS  PubMed  Google Scholar 

  178. Berger SH: Trifluoperazine and haloperidol: Sources of ejaculatory pain. Am J Psychiatry 136: 350, 1979

    CAS  PubMed  Google Scholar 

  179. Bors E, Comarr AE: Neurological disturbances of sexual function with special reference to 529 patients with spinal cord injury. Urol Rev 10: 191–222, 1960

    Google Scholar 

  180. Wyatt RJ, Fram DH, Buchbinder R, et al: Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Eng J Med 285: 987–991, 1971

    CAS  Google Scholar 

  181. Friedman S, Kantor I, Sobel S, et al: A follow-up study on the chemotherapy of neurodermatitis with a monoamine oxidase inhibitor. J Nerv Ment Dis 166: 349–357, 1978

    CAS  PubMed  Google Scholar 

  182. Hollander MH, Ban TA: Ejaculatio retarda due to phenelzine. Psychiatr J Univ Ottawa 4: 233–234, 1980

    Google Scholar 

  183. Rapp MS: Two cases of ejaculatory impairment related to phenelzine. Am J Psychiatry 136: 1200–1201, 1979

    CAS  PubMed  Google Scholar 

  184. Glass RM: Ejaculatory impairment from both phenelzine and imipramine with tinnitus from phenelzine. J Clin Psychopharmacol 1: 152–154, 1981

    CAS  PubMed  Google Scholar 

  185. Blair JH, Simpson GM, Kline KS: Monoamine oxidase inhibitor and sperm production. JAMA 181: 182, 1962

    Google Scholar 

  186. Davis J, Clyman MJ, Decker A, et al: Effect of phenelzine on semen in infertility: A preliminary report. Fertil Steril 17: 221–225, 1966

    CAS  PubMed  Google Scholar 

  187. Kohn RM: Nocturnal orthostatic syncope in pargyline therapy. JAMA 187: 229, 1964

    CAS  PubMed  Google Scholar 

  188. Simpson GM, Blair JH, Amuso D: Effects of anti-depressants on genitourinary function. Dis Nerv Syst 26: 787–789, 1965

    CAS  PubMed  Google Scholar 

  189. Bennett D: Treatment of ejaculatio praecox with monoamine-oxidase inhibitors. Lancet 1: 1309, 1961

    Google Scholar 

  190. Everett HC: The use of bethanechol chloride with tricyclic antidepressants. Am J Psychiatry 132: 1202–1204, 1975

    CAS  PubMed  Google Scholar 

  191. Couper-Smartt JD, Rodham R: A technique for surveying side-effects of tricyclic drugs with reference to reported sexual effects. J Int Med Res 1: 473–476, 1973

    CAS  PubMed  Google Scholar 

  192. Greenberg HR: Erectile impotence during the course of Tofranil therapy. Am J Psychiatry 121: 1021, 1965

    CAS  PubMed  Google Scholar 

  193. Ruskin DB, Goldner RD: Treatment of depressions in private practice with imipramine. Dis Nerv Syst 20: 391–399, 1959

    Google Scholar 

  194. Kahn MAM: Side effects of amitriptyline. Br Med J 3: 708, 1975

    Google Scholar 

  195. Hekimian LJ, Friedhoft AJ, Deever E: A comparison of the onset of action and therapeutic efficacy of amoxapine and amitriptyline. J Clin Psychiatry 39: 633–637, 1978

    CAS  PubMed  Google Scholar 

  196. Nininger JE: Inhibition of ejaculation by amitriptyline. Am J Psychiatry 135: 750–751, 1978

    CAS  PubMed  Google Scholar 

  197. Beaumont G: Sexual side-effects of clomipramine (Anafranil). J Int Med Res 5 (suppl): 37–44, 1977

    CAS  PubMed  Google Scholar 

  198. Beaumont G: Side-effects of toxicity of clomipramine. Br J Clin Pract (suppl 3 ): 51–53, 1979

    Google Scholar 

  199. Lasich AJ: Clinical evidence of a new antidepressant. Med Proc, Mediesae Bydiaes 14: 312–317, 1968

    Google Scholar 

  200. Wootten LW, Bailey RI: Experiences with clomipramine (Anafranil) in the treatment of the phobic anxiety states in general practice. J Int Med Res 3 (suppl 1): 101–107, 1975

    Google Scholar 

  201. Yassa R: Sexual disorders in the course of clomipramine treatment: A report of three cases. Can J Psychiatry 27: 148–149, 1982

    CAS  PubMed  Google Scholar 

  202. Clarke FC: The treatment of depression in general practice. SAfr Med J 43: 724–725, 1969

    CAS  Google Scholar 

  203. Anath J, Pechnold JC, Steern NVD, et al: Double-blind comparative study of chlori-mipramine in obsessive nerosis. Curr Ther Res 25: 703–709, 1979

    Google Scholar 

  204. Eaton H: Clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res 1: 432–434, 1973

    Google Scholar 

  205. Waxman DA: A general practitioner trial of clomipramine (Anafranil) in obsessions and phobias. J Int Med Res 3 (suppl 1): 94–100, 1975

    Google Scholar 

  206. McLean JD, Forsythe RG, Kapkin IA: Unusual side-effect of clomipramine associated with yawning. Can J Psychiatry 28: 569–570, 1983

    CAS  PubMed  Google Scholar 

  207. Schwarcz G: Case report of inhibition of ejaculation and retrograde ejaculation as side-effects of amoxapine. Am J Psychiatry 139: 233–234, 1982

    CAS  PubMed  Google Scholar 

  208. Kulik FA, Wilbur R: Case report of painful ejaculation as a side effect of amoxapine. Am J Psychiatry 139: 234–235, 1982

    CAS  PubMed  Google Scholar 

  209. Shen WW: Female orgasmic inhibition by amoxapine. Am J Psychiatry 139: 1221, 1982

    Google Scholar 

  210. Getzoff PL: Psychotropic drug induced male infertility: A case report. Infertility 1: 53–58, 1978

    CAS  PubMed  Google Scholar 

  211. Vinarova E, Uhlir 0, Stika L,. Side-effects of lithium administration. Activitas Nervosa Supperior (Praha) 14: 105–107, 1972

    CAS  Google Scholar 

  212. Scher M, Krieger JN, Jvergens S: Trazodone and priapism. Am J Psychiatry 140: 1362–1363, 1983

    CAS  PubMed  Google Scholar 

  213. Blay SL, Ferraz MPT, Calil HM: Lithium-induced male sexual impairment: Two case reports. J Clin Psychiatry 43: 497–498, 1982

    CAS  PubMed  Google Scholar 

  214. Magnus RV, Dean BC, Curry SH: Clorazepate: Double-blind crossover comparison of a single nightly dose with diazepam thrice daily in anxiety. Dis Nerv Syst 38: 317–321, 1977

    Google Scholar 

  215. General Practitioner Research Group: A single-dose anti-anxiety drug. Practitioner 215: 98–101, 1975

    Google Scholar 

  216. Usdin GL: Preliminary report on librium, a new psychopharmacologic agent. J Louisiana State Med Soc 112: 142–147, 1960

    CAS  Google Scholar 

  217. Hughes JM: Failure to ejaculate with chlordiazepoxide. Am J Psychiatry 121: 610–611, 1964

    CAS  PubMed  Google Scholar 

  218. Biron P: Diminished libido with Cimetidine therapy. Can Med Assoc J 121: 404–405, 1979

    CAS  PubMed Central  PubMed  Google Scholar 

  219. Gifford LM, Aevgle ME, Myerson RM, et al: Cimetidine postmarket outpatient surveillance program. JAMA 243: 1532–1536, 1980

    CAS  PubMed  Google Scholar 

  220. Wolfe MM: Impotence of Cimetidine treatment. N Engl J Med 300: 94, 1979

    CAS  PubMed  Google Scholar 

  221. Peden NR, Cargill JM, Browning MCK, et al: Male sexual dysfunction during treatment with Cimetidine. Br Med J 1: 659, 1979

    CAS  PubMed Central  PubMed  Google Scholar 

  222. Hall WW: Breast changes in males on cimitidine. N Engl ] Med 295: 841, 1976

    CAS  Google Scholar 

  223. Carlson HE, Ippoliti AF: Cimetidine, an H2-antihistamine, stimulates prolactin secretion in man. J Clin Endocrinol Metab 45: 367–370, 1977

    CAS  PubMed  Google Scholar 

  224. Adaikan PG, Karim SMM: Male sexual dysfunction during treatment with Cimetidine. Br Med J 1: 1282, 1283, 1979

    Google Scholar 

  225. Neri A, Aygen M, Zuckerman Z, et al: Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin. Arch Sexual Behav 9: 343–347, 1980

    CAS  Google Scholar 

  226. Lewinn EB: Gynecomastia during digitalis therapy. N Engl ] Med 248: 316–320, 1953

    CAS  Google Scholar 

  227. Navab A, Koss LG, LaDue JS: Estrogen-like activity of digitalis. JAMA 194: 30–32, 1965

    CAS  PubMed  Google Scholar 

  228. Stoffer SS, Hynes KM, Jiany NS, et al: Digoxin and abnormal serum hormone levels. JAMA 225: 1643–1644, 1973

    CAS  PubMed  Google Scholar 

  229. Duggan ML, Morgan C: Heparin: A cause of priapism? South Med J 63: 1131–1134, 1970

    CAS  PubMed  Google Scholar 

  230. Schneider J, Kaffarnik H: Impotence in patients treated with Clofibrate. Atherosclerosis 21: 455–457, 1975

    CAS  PubMed  Google Scholar 

  231. Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 231: 360–380, 1975

    Google Scholar 

  232. McHaffie DJ, Guz A, Johnston A: Impotence in patient on disopyramide. Lancet 1: 230, 1977

    Google Scholar 

  233. Admad S: Disopyramide and impotence. South Med J 73: 958, 1980

    Google Scholar 

  234. Shader RI, Greenblatt DJ: Belladonna alkaloids and synthetic anticholinergic: Uses and toxicity, in Shader RI (ed): Psychiatric Complicationa of Medical Drugs, New York, Raven Press, 1972

    Google Scholar 

  235. Schwartz NH, Robinson BD: Impotence due to methantheline bromide. NY State J Med 52: 1530, 1952

    CAS  Google Scholar 

  236. Wagner G, Brindley GS: Effects of atropine on erection. Presented at First Inter Conf Vas Impotence, New York, 1978

    Google Scholar 

  237. Wagner G, Green R: Impotence: Physiological, Psychological Surgical diagnosis and treatment. New York, Plenum Press, 1981.

    Google Scholar 

  238. Wagner G, Levin RJ: Effect of atropine and methylatropine on human vaginal blood flow, sexual arousal and climax. Acta Pharmacol Toxicol 46: 321–325, 1980

    CAS  Google Scholar 

  239. Lichter PR, Newman LP, Wheeler NC, et al: Patient tolerance to carbonic anhydrase inhibitors. Am ] Opthalmol 85: 495, 502, 1978

    Google Scholar 

  240. Wallace TR, Fraunfelder FT, Petursson GJ, et al: Decreased libido-a side effect of carbonic anhydrase inhibitor. Ann Opthalmol 11: 1563–1566, 1979

    CAS  Google Scholar 

  241. Epstein DL, Grant WM: Carbonic anhydrase inhibitor side effects. Arch Opthalmol 95: 1378–1382, 1977

    CAS  Google Scholar 

  242. Hedley DW, Maroun JA, Espir MLE: Evaluation of baclofer (Lioresal) for spasticity in multiple sclerosis. Postgrad Med ] 51: 615–618, 1975

    CAS  Google Scholar 

  243. Evans BE, Aledort LM: Inhibition of ejaculation due to epsilon aminocaproic acid. N Engl J Med 298: 166–167, 1978

    CAS  PubMed  Google Scholar 

  244. Carney DE, Tweddell ED: Double-blind evaluation of long acting diethylpropian hydrochloride in obese patients from a general practice. Med ] Aust 1: 13–15, 1975

    CAS  Google Scholar 

  245. Snyder S, Karacan I, Salis PJ: Disulfiram and nocturnal penile tumescence in the chronic alcoholic. Biol Psychiatry 16: 399–406, 1981

    CAS  PubMed  Google Scholar 

  246. Gale AS: Ketamine prevention of penile turgescence. JAMA 219: 1629, 1972

    CAS  PubMed  Google Scholar 

  247. Pietras JR, Cromie WJ, Duckett JW: Ketamine as a detumescence agent during hypospadias repair. ] of Urol 121: 654, 1979

    CAS  Google Scholar 

  248. Chapman RM, Rees LH, Sutcliffe SB, et al: Cyclic combination chemotherapy and gonadal function. Lancet 1: 285–289, 1979

    CAS  PubMed  Google Scholar 

  249. Shalet SM: Effects of cancer chemotherapy on gonadal function of patients. Cancer Treatment Rev 7: 141–152, 1980

    CAS  Google Scholar 

  250. Thachil JV, Jewett MAS, Rider WD: The effects of cancer and cancer therapy on male fertility. J Urol 126: 141–145, 1981

    CAS  PubMed  Google Scholar 

  251. Schilsky RL, Lewis BJ, Sherins RJ, et al: Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med 93: 109–114, 1980

    CAS  PubMed  Google Scholar 

  252. Greenberg MS, Aisenberg AC, Arky RA: Gynecomastia after chemotherapy. Clin Res 27: 386A, 1979

    Google Scholar 

  253. Buffin J: Pharmacosexology: The effects of drugs on sexual function. A review. J Psychoactive Drugs 14: 5–44, 1982

    Google Scholar 

  254. Pinder RM, Brogden RN, Sawyer PR, et al: Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity. Drugs 10: 241–323, 1982

    Google Scholar 

  255. Howard DJ,Rees JR: Long term perhexiline maleate and liver function. Br Med] 1: 133, 1976

    Google Scholar 

  256. Pilcher J, Chandraseklhar KP, Rees JR, et al: Long-term assessment of perhixiline maleate in angina pectoris. Postgrad Med ] (April suppl):ll-118, 1973

    Google Scholar 

  257. Peck AW: Impotence in farm workers. Br Med ] 1: 690, 1970

    CAS  Google Scholar 

  258. Espir MLE, Hall JW, Schirreffs JG, et al: Impotence in farm workers using toxic chemicals. Br Med ] 1: 423–425, 1970

    CAS  Google Scholar 

  259. Layzer RB: Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet 1: 1227–1230, 1978

    Google Scholar 

  260. Schiavi RC, White D: Androgens and male sexual function: A review of human studies. J Sex Marital Ther 2: 214–228, 1976

    CAS  PubMed  Google Scholar 

  261. Segraves RT, Schoenberg HW, Ivanoff J: Serum testosterone and prolactin levels in erectile dysfunction. J Sex Marital Ther 9: 19–26, 1983

    CAS  PubMed  Google Scholar 

  262. Rose RM: The psychological effects of androgens and estrogens-A review, in Shader RI (ed): Psychiatric Complications of Medical Drugs. New York, Raven Press, 1972

    Google Scholar 

  263. Freund K: Therapeutic sex drive reduction. Acta Psychiatr Scand (suppl 287 ): 5–38, 1980

    CAS  Google Scholar 

  264. Laschet U, Laschet L: Three years clinical results with cyproteroneacetate in the inhibiting regulation of male sexuality. Acta Endocrinol (suppl): 138–183, 1969

    Google Scholar 

  265. Jeffcoate WJ, Matthews RW, Edwards CRW, et al: The effect of cyproterone acetate on serum testosterone, Lh, FSH, and prolactin in male sexual offenders. Clin Endocrinol 13: 189–195, 1980

    CAS  Google Scholar 

  266. Boas CVE: Cyproteronecetate in sexuological outpatient practice. Psychiatr Neurol Neurochir 76: 151–154, 1973

    PubMed  Google Scholar 

  267. Bosch JJ: Manipulation of sexual behavior by anti-androgens. Psychiatr Neurol Neurochir 76: 147–149, 1973

    Google Scholar 

  268. Bancroft J, Tennent G, Loucas K, et al: The control of deviant sexual behavior by drugs: 1, Behavioral changes following oestrogens and antiandrogens. Br J Psychiatry 125: 310–315, 1974

    CAS  PubMed  Google Scholar 

  269. Cooper AJ, Ismail AA, Phanjoo AL, Antiandrogen (cyprotone acetate) therapy in deviant hypersexuality. Br Psychiatryll0: 59–63, 1972

    Google Scholar 

  270. Berlin F, Meinecke C: Treatment of sex offenders with antiandrogenic medication. Am J Psychiatry 138: 601–602, 1981

    CAS  PubMed  Google Scholar 

  271. Paulson DF, Kane RP: Medrogestone: A prospective study in the pharmaceutical management of benign prostatic hyperplasia. J Urol 113: 811–815, 1975

    CAS  PubMed  Google Scholar 

  272. Palanca E, Juco W: Conservative treatment of benign prostatic hyperplasia. Curr Med Res Opinion 4: 513–520, 1977

    CAS  Google Scholar 

  273. Meiraz D, Margolin Y, Leu-Ran A, et al: Treatment of benign prostatic hyperplasia with hydroxy-progesterone-caprovate: Placebo-controlled study. Urology 9: 144–148, 1977

    CAS  PubMed  Google Scholar 

  274. Hollister LE: The mystique of social drugs and sex, in Sandler M, Gessa GL (eds): Sexual behavior: Pharmacology and biochemistry New York, Raven Press, 1975

    Google Scholar 

  275. Carter CS, Davis JM: Effects of drugs on sexual arousal and performance, in Meyer JK (ed): Clinical Management of Sexual Disorders. Baltimore, Williams & Wilkins Co., 1976

    Google Scholar 

  276. Bignani G: Pharmacologic influences on mating behavior in the male rat. Psychophar-macologia 10: 44–58, 1966

    Google Scholar 

  277. Parr D: Sexual aspects of drug abuse in narcotic addicts. Br J Addiction 71: 261–268, 1976

    CAS  Google Scholar 

  278. Waud SP: The effects of toxic doses of benzyl methyl carbinamine (Benzedrine) in man. JAMA 110: 206, 1938

    CAS  Google Scholar 

  279. Bett WR: Benzedrine sulphate in clinical medicine. Postgrad Med J 22: 205, 1946

    CAS  PubMed Central  PubMed  Google Scholar 

  280. Carr RB: Acute psychotic reaction after inhaling methylamphetamine. Br Med J 1: 1476, 1954

    CAS  PubMed Central  PubMed  Google Scholar 

  281. Monroe RR, Drell HJ: Oral use of stimulants obtained from inhalers. JAMA 135: 909, 1947

    CAS  Google Scholar 

  282. Angrist B, Gershon S: Clinical effects of amphetamine and L-dopa on sexuality and aggression. Compulsive Psychiatry 17: 715–722, 1976

    CAS  Google Scholar 

  283. Bell DS, Trethowan WH: Amphetamine addiction and disturbed sexuality. Arch Gen Psychiatry 4: 74–78, 1961

    Google Scholar 

  284. Gossop MR, Connell PH: Drug dependence and sexual dysfunction: A comparison of intravenous users of narcotics and oral users of amphetamines. Br J Psychiatry 124: 431–434, 1974

    CAS  PubMed  Google Scholar 

  285. Ellinwood EH, Rockwell WJK: Effect of drug use on sexual behavior. Med Aspects Hum Sexuality 9: 10–31, 1975

    Google Scholar 

  286. Connell PH: Amphetamine Psychosis, Maudsley Monograph No. 5. London, Chapman and Hall, 1958

    Google Scholar 

  287. Gay GR, Newmeyer JA, Elion RA, Drug-sex practice in the Haight-Ashbury or “the sensuous hippie,” in Sandler M, Gessa GL (eds): Sexual Behavior: Pharmacology and Biochemistry. New York, Raven Press, 1975

    Google Scholar 

  288. Angtist B, Gershon S: Amphetamine abuse in New York City-1966–1968. Semin Psychiatry 1: 195–207, 1969

    Google Scholar 

  289. Angrist BM, Gershon S: Psychiatric sequelae of amphetamine use, in Shader RI (ed): Psychiatric Complications of Medical Drugs. New York, Raven Press, 1972

    Google Scholar 

  290. Gay GR, Sheppard CW: Sex in the drug culture. Med Aspects Hum Sexuality 6: 28–35, 1972

    Google Scholar 

  291. Greaves G: Sexual disturbances among chronic amphetamine users. J Nerv Ment Dis 155: 363–365, 1972

    CAS  PubMed  Google Scholar 

  292. Chopra GS: Man and marijuana. Int J Addictions 4: 215–247, 1969

    Google Scholar 

  293. Harmon J, Aliapoulios MA: Gynecomastia in marijuana users. N Engl ] Med 287: 936, 1972

    CAS  Google Scholar 

  294. Kolodny RC, Masters WH, Kolodner RM, et al: Depression of plasma testosterone levels after chronic intensive marijuana use. N Engl J Med 290: 872–874, 1974

    CAS  PubMed  Google Scholar 

  295. Mendelson JH, Kuehnle J, Ellingboe J, et al: Plasma testosterone levels before, during, and after chronic marijuana smoking. N Engl J Med 291: 1051–1055, 1974

    CAS  PubMed  Google Scholar 

  296. Merari A, Barak A, Plaves M: Effect of 1 (2)-tetrahydrocannabinol on copulation in the male rat. Psychopharmacologia 28: 243–246, 1973

    CAS  PubMed  Google Scholar 

  297. Siegel RK: Cocaine: Recreational use and intoxication, in Peterson, RC, Stillman RC (eds): Cocaine 1977, NIDA Research Monograph 13. Rockville, Maryland, Department of Health, Education, and Welfare, 1977

    Google Scholar 

  298. Everett GM: Amylonitrite (“poppers”) as an aphrodisiac, in Sandler M, Gessa GL (eds): Sexual Behavior: Pharmacology and Biochemistry. New York, Raven Press, 1975

    Google Scholar 

  299. Welti RS, Brodsky JB: Treatment of intraoperative penile tumescence. J Urol 124: 925–926, 1980

    CAS  PubMed  Google Scholar 

  300. DeLeon G, Wexler HK: Heroin addiction: Its relation to sexual behavior and sexual experience. ] Abnorm Psychol 81: 36–38, 1973

    CAS  Google Scholar 

  301. Wieland WF, Yunger M: Sexual effects and side effects of heroin and methadone. Proceedings of the Third National Conference on Methadone. Washington, DC, US Government Printing Office, 1971

    Google Scholar 

  302. Mathis JL: Sexual aspects of heroin addiction. Med Aspects Hum Sexuality 4: 98–103, 1970

    Google Scholar 

  303. Chambers CD, Brill L, Langrod J: Physiological and psychological side-effects reported during maintenance therapy, in Chambers CD, Brill L (eds): Methadone: Experience and Issues. New York, Behavioral Publications, 1973

    Google Scholar 

  304. Goldstein A: Blind dosage comparisons and other studies in a large methadone program. J Psychedelic Drugs 4: 177–181, 1971

    Google Scholar 

  305. Goldstein A: Blind controlled dosage comparison with methadone in 200 patients. Proceedings of the Third National Conference on Methadone Treatment. Washington, DC, US Government Printing Office, 1971

    Google Scholar 

  306. Goldstein A, Judson BA: Efficacy and side effects of 3 widely different methadone doses. Proceedings of the Fifth National Conference on Methadone Treatment. Washington DC, US Government Printing Office, 1973

    Google Scholar 

  307. Martin WR, Jasinski D. R., Haertzen CA, et al: Methadone-a réévaluation. Arch Gen Pscyhiatry 28: 286–295, 1973

    CAS  Google Scholar 

  308. Garbutt G, Goldstein A: Blind comparison of three methadone maintenance dosages in 180 patients. Proceeding of the Fourth National Conference on Methadone Treatment. New York, National Association for Prevention of Addiction to Narcotics, 1972

    Google Scholar 

  309. Bloom WA, Butcher BT: Methadone side-effects and related symptoms in 200 methadone maintenance patients. Proceedings of the Third National Conference on Methadone Treatment. Washington, DC, US Government Printing Office, 1971

    Google Scholar 

  310. Crowley TJ, Simpson R: Methadone dose and human sexual behavior. Int J Addictions 13: 285–295, 1978

    CAS  Google Scholar 

  311. Cushman P, Dole VP: Detoxification of rehabilitated methadone-maintained patients. JAMA 226: 747–752, 1973

    CAS  PubMed  Google Scholar 

  312. Mintz J, O’Hare K, O’Brien CP, et al: Sexual problems of heroin addicts. Arch Gen Psychiatry 31: 700–703, 1974

    CAS  PubMed  Google Scholar 

  313. Cicero TJ, Bell RD, Wiest WG, et al: Function of the male sex organs in heroin and methadone users. N Engl ] Med 292: 882–887, 1975

    CAS  Google Scholar 

  314. Cushman P: Sexual behavior in heroin addiction and methadone maintenance. NY State J Med 72: 1261–1265, 1972

    Google Scholar 

  315. Smith DE, Moser C, Wesson DR, et al: A clinical guide to the diagnosis and treatment of heroin-related sexual dysfunction. J Psychoactive Drugs 14: 91–99, 1982

    CAS  PubMed  Google Scholar 

  316. Kneek MJ: Medical safety and side effects of methadone in tolerant individuals. JAMA 223: 665–668, 1973

    Google Scholar 

  317. Espejo R, Hogben G, Stimmel B: Sexual performance of men on methadone maintenance. Proceeding of the National Conference on Methadone Treatment, New York, 1973

    Google Scholar 

  318. Senay EC, Dorus W, Renault PF: Methadyl acetate and methadone. JAMA 237: 138–142, 1977

    CAS  PubMed  Google Scholar 

  319. Mirin SM, Meyer RE, Mendelson JH, et al: Opiate use and sexual function. Am J Psychiatry 137: 909–915, 1980

    CAS  PubMed  Google Scholar 

  320. Cushman P: Plasma testosterone in narcotic addiction. Am J Med 55: 452–458, 1973

    CAS  PubMed  Google Scholar 

  321. Glick BB, Baughman WL, Jessen JN, et al: Endogenous opiate systems and primate reproduction: Inability of naloxone to induce sexual activity in Rhesus males. Arch Sexual Behav 11: 267–275, 1982

    CAS  Google Scholar 

  322. Bors E, Turner RD: Neurologic Urology, in Kaufmen JJ (eds): Advances in Diagnostic Urology. Boston, Little Brown, 1964

    Google Scholar 

  323. Weiss HD: The physiology of human penile erection. Ann Intern Med 76: 793–799, 1972

    CAS  PubMed  Google Scholar 

  324. Domer F, Wessler G, Brown R, Charles C: Involvement of the sympathetic nervous system in the urinary bladder internal sphincter and in penile erections in the anesthetized cat. Invest Urol 15: 404–407, 1978

    CAS  PubMed  Google Scholar 

  325. Dors LD, Brody MJ: Hemodynamic mechanisms of erections in the canine penis. Am J Physiol 213: 1526–1531, 1967

    Google Scholar 

  326. Melman A, Henry D, Felton D, et al: Alternation of the penile corpora in patients with erectile impotence. Invest Urol 17: 474–477, 1980

    CAS  PubMed  Google Scholar 

  327. Benson G, McConnell J, Lipschultz L, et al: Neuromorphology and neuropharmacology of the human penis: an in vitro study. J Clin Invest 65: 506–513, 1980

    CAS  PubMed Central  PubMed  Google Scholar 

  328. Benson GS, McConnell J A, Schmidt WA: Penile polsters: Functional structures or atherosclerotic changes? J Urol 125: 800–803, 1981

    CAS  PubMed  Google Scholar 

  329. Gessa GL, Tagliamonte A: Possible role of brain serotonin and dopamine in controlling male sexual behavior. Adv Biochem Psychopharmacol 11: 217–228, 1974

    CAS  PubMed  Google Scholar 

  330. Ghadiran AM, Chovinard G, Annable L: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 170: 463–467, 1982

    Google Scholar 

  331. Gross MD: Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants. Am J Psychiatry 139: 1193–1194, 1982

    CAS  PubMed  Google Scholar 

  332. Shen WW, Mallya AR: Psychotropic-induced sexual inhibition. Am J Psychiatry 140: 514–515, 1983

    CAS  PubMed  Google Scholar 

  333. Nurnberg HG, Ambrosini PJ: Urinary incontinence in patients receiving neuroleptics. J Clin Psychiatry 40: 271–274, 1979

    CAS  PubMed  Google Scholar 

  334. Shenoy RS: Nocturnal enuresis caused by psychotropic drugs. Am ] Psychiatry 137: 739–740, 1980

    CAS  PubMed  Google Scholar 

  335. Nakanishi H, Kaneko M: Is thioridazine-induced ejaculation failure peripheral? Res Commun Ciin Pathol Pharmacol 19: 549–552, 1978

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Tulane University Medical Center, New Orleans, Louisiana, 70112, USA

    R. Taylor Segraves

  2. Department of Surgery, University of Iowa, Iowa City, Iowa, 52240, USA

    Robert Madsen

  3. Department of Psychology and Ecology, University of Illinois, Champaign, Illinois, 61820, USA

    C. Sue Carter

  4. Department of Ethology and Evolution, University of Illinois, Champaign, Illinois, 61820, USA

    C. Sue Carter

  5. Illinois State Psychiatric Institute, University of Illinois, Chicago, Illinois, 60612, USA

    John M. Davis

  6. Department of Psychiatry, University of Illinois, Chicago, Illinois, 60612, USA

    John M. Davis

Authors
  1. R. Taylor Segraves
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Madsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Sue Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John M. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Tulane University, New Orleans, Louisiana, USA

    R. Taylor Segraves

  2. University of Chicago, Chicago, Illinois, USA

    R. Taylor Segraves  & Harry W. Schoenberg  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Plenum Publishing Corporation

About this chapter

Cite this chapter

Segraves, R.T., Madsen, R., Carter, C.S., Davis, J.M. (1985). Erectile Dysfunction Associated with Pharmacological Agents. In: Segraves, R.T., Schoenberg, H.W. (eds) Diagnosis and Treatment of Erectile Disturbances. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-9409-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-9409-3_2

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4615-9411-6

  • Online ISBN: 978-1-4615-9409-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation